N-Benzylacetamidine (hydrobromide) |
| Catalog No.GC12677 |
iNOS inhibitor
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 186545-76-6
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
IC50: 0.20 μM: inhibits inducible nitric oxide synthases (iNOS).
IC50: 350 μM: blocks endothelial nitric oxide synthases (eNOS).
N-Benzylacetamidine is a potent and selective inhibitor of iNOS compared to eNOS. NOS is essential to the formation of nitric oxide (NO) via the NADPH- and O2-dependent oxidation of L-arginine, which plays a role in regulating many pathological and physiological processes, including smooth muscle relaxation and neurotransmission. INOS contributes to immune response and inflammation while eNOS plays a vital role in regulating vascular tone.
In vitro: N-Benzylacetamidine showed good iNOS and almost negligible eNOS inhibition in THP-1 cells, a human myelomonocytic leukemia cell line [1].
In vivo: Up to now, in vivo study of N-Benzylacetamidine is still in the development stage.
Reference:
[1]. Maccallini, C., Patruno, A., Besker, N., Ali, J., Ammazzalorso, A., & De Filippis, B. et al. Synthesis, Biological Evaluation, and Docking Studies of N-Substituted Acetamidines as Selective Inhibitors of Inducible Nitric Oxide Synthase. Journal of Medicinal Chemistry. 2009; 52(5): 1481-1485.
Average Rating: 5 (Based on Reviews and 10 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *